Sanofi to build EUR 490 million vaccine production facility in France16 Jun 2020
The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccines
Sanofi will invest EUR 490 million over five years in building a vaccine production facility in France as it continues to scale up its manufacturing capacity to fight future pandemic risks, the French pharmaceutical company said on Tuesday.
The plant, Evolutive Vaccine Facility, in Neuville sur Saône, France is designed around a central unit housing several fully digital production modules that make it possible to produce three to four vaccines simultaneously, Sanofi said.
However, this modularity will make it possible to rapidly prioritize the production of a specific vaccine if the need arises, it added.
The state-of-the-art industrial site, which is expected to create 200 new jobs, will enable the pharma firm’s vaccine unit, Sanofi Pasteur, to be the first pharmaceutical manufacturer to benefit from such an industrial tool and to secure vaccine supplies in the event of new pandemics, Sanofi said.
Sanofi has also committed to investing EUR 120 million to create a new R&D centre in France at the Sanofi Pasteur site in Marcy-l'Etoile to develop future vaccines.
The digital facility will house highly specialized laboratories that will enable the development of vaccines against emerging diseases and pandemic risks.
The drug firm said it hopes the centre will become “a world reference for pre-clinical research and pharmaceutical and clinical development.”
“By investing in a new industrial site and a R&D centre, Sanofi positions France at the core of its strategy, aiming to make France a world-class centre of excellence in vaccine research and production,” said Sanofi CEO Paul Hudson.
SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment
7 Jul 2020
The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.Read more
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail
7 Jul 2020
The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.Read more
Ajinomoto introduces fast track platform for drug product manufacturing
30 Jun 2020
AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.Read more
Piramal acquires solid oral dosage drug product facility from G&W Laboratories
22 Jun 2020
The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.Read more
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment
22 Jun 2020
The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.Read more
Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's
8 Jun 2020
Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.Read more
Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates
2 Jun 2020
The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.Read more
Changes needed to prevent controversial pay-for-delay pharma deals
26 May 2020
Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.Read more
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient
26 May 2020
SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.Read more
AbCellera and Lilly seal multi-year antibody discovery collaboration
25 May 2020
AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation